Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11222 Views
-
Last post by NHE
-
- 0 Replies
- 1043 Views
-
Last post by NHE
-
- 0 Replies
- 1844 Views
-
Last post by frodo
-
- 0 Replies
- 1211 Views
-
Last post by frodo
-
- 0 Replies
- 1970 Views
-
Last post by NHE
-
- 0 Replies
- 1675 Views
-
Last post by frodo
-
- 0 Replies
- 1186 Views
-
Last post by NHE
-
- 1 Replies
- 1691 Views
-
Last post by frodo
-
- 0 Replies
- 2238 Views
-
Last post by NHE